Bradley Wiggins has come under further pressure before he appears on television to explain why he had three Therapeutic Use Exception (TUE) certificates for the power corticoid Triamcinolone Acetonide before riding the Tour de France and Giro d'Italia in 2011, 2012 and 2013.
The 2012 Tour de France winner issued two statements last weekend when his TUE data first emerged via the Fancy Bears leaks but with Team Sky and others involved still failing to speak openly about what happen and to fully explain their positions, others have filled the void, raising doubts Wiggins' need for the supposed asthma drug.
The highly respect BBC Newsnight programme stepped away from reporting on politics in Britain and the USA to dedicate a 10-minute slot to the Wiggins TUE story. They spoke to Wiggins doctor during his time at the Garmin team in 2009, Dr. Prentice Steffen, when he finished in the Tour de France, along with former rider and convicted doper Michael Rasmussen, who was eliminated from the 2007 Tour de France after lying about his whereabouts before the race. He has since made a total confession about his complex doping programme and lifts the lid on racing and doping for a Danish newspaper.
ADVERTISEMENT
While it must be stressed that Wiggins and Team Sky stayed on the right side of legality, with Wiggins' TUE issued for diagnosed asthma and pollen allergies, the whole process has sparked serious questions over the policy towards TUEs, the grey area of corticoid steroid use and transparency.
The timing of the application for the TUE has also raised eyebrows within the cycling community, with two leading experts and Steffen questioning the necessity of needing the steroid in the build-up to major races. Steffen spoke to Cyclingnews earlier in the week and reiterated his thoughts to the BBC.
Though he refused to comment on Wiggins' private medical records, Steffen was said he was surprised he needed this sort of intervention.
You can read more at Cyclingnews.com
via Cyclingnews Latest News http://ift.tt/2dqpEdC
No comments:
Post a Comment